Technical Advantage

Technological Advantages

Technical Advantage

Beijing Anding Hospital Affiliated with Capital Medical University


Capital Medical University's Beijing Anding Hospital is one of China's earliest public psychiatric hospitals and a Grade III Class A specialized hospital directly managed by the Beijing Hospital Management Center. It is specifically focused on outpatient and inpatient care for acute and severe mental disorders, as well as consultation services for complex and challenging mental health cases. Additionally, the hospital provides psychological crisis intervention during sudden disaster events and offers mental health services to the general public. In January 2020, the two institutions signed a research collaboration agreement to jointly conduct preclinical studies on the use of human bone marrow mesenchymal stem cells for treating autism.

On March 11, 2025, Jiuzhitang Maker’s third stem-cell-based new drug received approval for clinical trials (Acceptance No.: CXSL2400859), with the indication targeting autism spectrum disorder. On August 26, 2025, the clinical trial officially kicked off, with Jiuzhitang Maker collaborating with Beijing Anding Hospital to conduct a Phase I clinical trial evaluating hBMMSC therapy for autism spectrum disorder.